Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: OnabotulinumtoxinA (BOTOX®) Clear all
Completed Phase 4 Interventional Results available

Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine

NCT02037425
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT01107392
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin Type A, Normal saline
Drug
Lead sponsor
Allergan
Industry
Eligibility
45 Years and older · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00311376
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal Saline (Placebo); botulinum toxin Type A (200U), Normal Saline (Placebo); botulinum toxin Type A (300U)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Skin Quality Improvement

NCT03097835
View directory record Official record
Conditions
Skin Quality
Interventions
Hyper-Diluted Botox, Topical anesthesia, 0.9% saline solution
Drug · Other
Lead sponsor
Steve Yoelin M.D. Medical Associates, Inc.
Other
Eligibility
35 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 17, 2026, 2:06 PM EDT
Recruiting Phase 2 Interventional

Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT03571334
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
IncobotulinumtoxinA (Xeomin®, Merz) (INA), Normal saline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

NCT00876447
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Middlebury, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 17, 2026, 2:06 PM EDT
Terminated Not applicable Interventional Results available

Botulinum Toxin A for Herpes Labialis

NCT01225341
View directory record Official record
Conditions
Herpes Labialis
Interventions
onabotulinumtoxinA, Bacteriostatic normal saline
Drug · Other
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 17, 2026, 2:06 PM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

NCT03052764
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence
Interventions
onabotulinumtoxinA, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 17, 2026, 2:06 PM EDT
Not listed Early Phase 1 Interventional

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

NCT05485207
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Transvaginal botulinum toxin A (BTA) injection
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Not applicable Interventional Results available

Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis

NCT01811004
View directory record Official record
Conditions
Hyperhidrosis
Interventions
miraDry, Nd:YAG Laser, Botox®
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 17, 2026, 2:06 PM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Chronic Migraine

NCT02074163
View directory record Official record
Conditions
Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24,, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

NCT01662492
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00461292
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal saline (Placebo); botulinum toxin Type A (200U), Normal saline (Placebo); botulinum toxin Type A (300U)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Middlebury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of OnabotulinumtoxinA (BOTOX®) on Stress

NCT06778421
View directory record Official record
Conditions
Stress (Psychology), Stress, Healthy Adult Female Participants, Stress, Psychologic, Stress, Psychological Cumulative, Stress, Physiological, Stress Response, Stress Levels, Stress Perception
Interventions
Intramuscular injection, OnabotulinumtoxinA (Botox®) Injections, Sodium Chloride
Procedure · Drug · Other
Lead sponsor
Center for Advanced Facial Plastic Surgery
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 17, 2026, 2:06 PM EDT
Terminated Phase 4 Interventional Results available

Real World Effectiveness of Eptinezumab in Participants With Migraine

NCT05284019
View directory record Official record
Conditions
Migraine
Interventions
Eptinezumab, Erenumab, Onabotulinumtoxin-A, Fremanezumab, Galcanezumab
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Gilbert, Arizona • Stamford, Connecticut • Palmetto Bay, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 2 Interventional

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

NCT00234507
View directory record Official record
Conditions
Blepharospasm
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
14
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 4 Interventional

A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis

NCT00168415
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

NCT00257660
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

NCT02718118
View directory record Official record
Conditions
Glabellar Lines, Wrinkles
Interventions
Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Greenwood Village, Colorado • Coral Gables, Florida • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 4 Interventional

A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction

NCT03199534
View directory record Official record
Conditions
Pelvic Pain, Dyspareunia, Pelvic Floor Dysfunction
Interventions
Botulinum toxin A 50u, Botulinum toxin A 100u, Botulinum toxin A 150u
Drug
Lead sponsor
EvergreenHealth
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 17, 2026, 2:06 PM EDT
Recruiting Early Phase 1 Interventional

Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms

NCT07648290
View directory record Official record
Conditions
Overactive Bladder
Interventions
Macrobid® Capsules 100 mg, Standard Medical Care (SMC)
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children

NCT02106351
View directory record Official record
Conditions
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

NCT01575054
View directory record Official record
Conditions
Muscle Spasticity
Interventions
botulinum toxin Type A, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 85 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Downey, California • Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 17, 2026, 2:06 PM EDT